Method of treating hepatitis C infection
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides the use of PEG-IFN-α conjugates in association with ribavirin for the treatment of chronic hepatitis C infections. The present invention also provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of PEG-IFN-α conjugate in association with an amount of ribavirin effective to treat hepatitis C.
19 Citations
13 Claims
-
1-5. -5. (Cancelled)
-
6. (Originally presented) A method for treating chronic hepatitis C infections comprising administering a PEG-IFN-α
- conjugate having the formula;
- View Dependent Claims (7, 8, 9, 11, 12)
- conjugate having the formula;
-
10. (Cancelled)
-
13. A method for treating chronic hepatitis C infections comprising:
-
a) administering a PEG-IFN-α
conjugate having the formula;
where R and R′
are methyl, X is NH, and n and n′
are individually or both either 420 or 520, wherein the PEG-IFN-α
2A conjugate is administered once a week in a dosage of from about 150 μ
g to about 250 μ
g of and co-administering ribavirin daily in a dosage of from about 800 mg to about 1200 mg of ribavirin per day;
b) continuing the administration of drug in accordance with a) for a period of 12 weeks;
c) testing the patient treated in accordance with b) for HCV-RNA titer or serum ALT; and
d) continuing the administration of drug in accordance with a) to only those patients tested in c) who have at least a one (1) log 10 unit decrease in viral titer or who have a 50% decrease in or normalization of serum ALT levels until a total treatment period of 48 weeks has been completed.
-
Specification